1. Home
  2. PCSA vs MITQ Comparison

PCSA vs MITQ Comparison

Compare PCSA & MITQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Processa Pharmaceuticals Inc.

PCSA

Processa Pharmaceuticals Inc.

HOLD

Current Price

$3.56

Market Cap

8.0M

Sector

Health Care

ML Signal

HOLD

Logo Moving iMage Technologies Inc.

MITQ

Moving iMage Technologies Inc.

HOLD

Current Price

$0.77

Market Cap

6.7M

ML Signal

HOLD

Company Overview

Basic Information
Metric
PCSA
MITQ
Founded
2011
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Telecommunications Equipment
Sector
Health Care
Telecommunications
Exchange
Nasdaq
Nasdaq
Market Cap
8.0M
6.7M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
PCSA
MITQ
Price
$3.56
$0.77
Analyst Decision
Strong Buy
Analyst Count
1
0
Target Price
$25.00
N/A
AVG Volume (30 Days)
321.0K
42.3K
Earning Date
11-06-2025
02-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$18,477,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.74
$0.50
52 Week High
$22.80
$1.66

Technical Indicators

Market Signals
Indicator
PCSA
MITQ
Relative Strength Index (RSI) 59.91 58.13
Support Level $3.07 $0.65
Resistance Level $3.80 $0.80
Average True Range (ATR) 0.31 0.05
MACD -0.08 0.01
Stochastic Oscillator 67.27 77.74

Price Performance

Historical Comparison
PCSA
MITQ

About PCSA Processa Pharmaceuticals Inc.

Processa Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on utilizing its regulatory science approach in the development of Next Generation Chemotherapy (NGC) oncology drug products. The company's strategic prioritization is to advance its pipeline of NGC proprietary small-molecule oncology drugs. The NGC products are new chemical entities, but the company works by changing the metabolism, distribution, and/or elimination of already FDA-approved cancer drugs or their active metabolites while maintaining the mechanism of how the drug kills cancer cells. The three NGC treatments in its pipeline are PCS6422 (also referred to as NGC-Cap), PCS3117, also referred to as NGC-Gemcitabine (NGC-Gem), and PCS11T, also referred to as NGC-Irinotecan (NGC-Iri).

About MITQ Moving iMage Technologies Inc.

Moving iMage Technologies Inc is engaged in providing designed equipment as well as other off the shelf cinema products needed for contemporary cinema requirements. It offers technical, design and consulting services such as custom engineering, systems design, integration and installation and digital technology, as well as software solutions for operations enhancement and theatre management.

Share on Social Networks: